London Commodities Consultancy, CRU, To Spotlight Prescriptive Analytics for Monetizing Data at Big Data LDN, The UK’s Leading Data and Analytics Event
The Chief Technology Officer and Co-founder of Pyramid Analytics (Pyramid), Avi Perez, will deliver a session with Will Blake, Chief Technology Officer of CRU, a global provider of business intelligence and consulting services for the global metals, mining and fertilizer industries, at Big Data LDN (London) on Wednesday 21st September at 12:40 p.m. BST at Olympia London. This historic Victorian exhibition space was founded in 1886 and is steps away from the TfL Kensington (Olympia) station.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005057/en/
CRU is a global provider of business intelligence and consulting services for the global metals, mining and fertilizer industries. The headquarters of CRU is located in the heart of London. Will Blake, Chief Technology Officer, will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
Key Points:
- CRU is a leading London commodities consultancy, relied upon by its clients for expert insight and data on the global metals, mining and fertilizer industries.
- Pyramid Analytics is the provider of the Pyramid Decision Intelligence Platform, the only purpose-built, unified Decision Intelligence Platform.
- Will Blake and Avi Perez will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
- This panel discussion will take place from 12:40 p.m. – 1:10 p.m. BST in the Modern Analytics Theatre at Big Data LDN.
- Join us at stand 435 to meet the Pyramid team, see demos of the Pyramid Platform, and learn how Decision Intelligence can transform your relationship with data.
- Register for your free tickets and find out more about the session here.
Why Attend
Big Data LDN is a major annual event for the UK data and analytics community, regularly bringing together more than 9,000 leading industry experts and practitioners from around the world for two days packed with seminars and exhibits at the Olympia in the heart of London.
-
Wednesday September 21, 12:40 p.m. – 1:10 p.m. in the Modern Analytics Theatre.
Decision Intelligence and Prescriptive Analytics: How CRU uses Pyramid to Drive its Data Analytic Solutions and Help Businesses Make More Informed Decisions
Presenters: Will Blake, Chief Technology Officer at CRU, and Avi Perez, Chief Technology Officer at Pyramid Analytics
Abstract: This session will be a discussion between two CTOs, both experts on data analytics. It will explore how CRU uses the Pyramid Decision Intelligence Platform within its data analytics pipelines, supporting market analysis and commodity price assessments
Blake and Perez will reveal how CRU restructured its approach to analytics, phasing out siloed approaches that relied on different tools and used the Pyramid Decision Intelligence Platform within its data analytics pipelines
Crucially, Decision Intelligence is founded on the principle of helping anyone secure data-driven insights to make faster, more intelligent decisions. CRU put this principle into action, using prescriptive analytics and Decision Intelligence to tackle major challenges such as reducing carbon emissions and other ESG initiatives. In so doing, CRU continues to transform commodity market data into a valuable business asset.
Decision Intelligence is the Next Big Data Analytics Innovation
“Artificial Intelligence (AI) is an increasingly important analytics technology. But AI to date is limited to highly-trained practitioners, and until now, there has been no easy way to integrate the essential AI components of Data Prep, Business Analytics, and Data Science. The Pyramid Decision Intelligence Platform meets this need: its Decision Intelligence solutions go beyond traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. The Pyramid Platform lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards,” said Blake.
In particular, the Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Decision Intelligence is High-Growth Segment of Augmented Analytics
The growth potential of Decision Intelligence is enormous. Gartner predicts that “more than 33%” of large organizations will be using Decision Intelligence by 2023. Similarly, worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a recent update from IDC. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period is predicted to be 12.8%.
Pyramid is helping to define this growing market.
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005057/en/
Contact information
UK
Alex Izza
Resonance
+44 759 189 9654
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom